Ophthalmology – Adie (Tonic) Pupil


Adie tonic pupil is a benign neurological condition characterized by idiopathic postganglionic parasympathetic denervation of the iris sphincter, followed by aberrant reinnervation. This results in a pupil that reacts poorly to light but better to near stimuli, a phenomenon known as light-near dissociation, along with slow redilation after accommodation. At initial presentation, the condition is unilateral in approximately 80% of cases, although about 4% of patients per year develop involvement of the fellow eye. The affected pupil is typically larger early on but may gradually become smaller than the normal pupil over time due to progressive miosis.


The condition has an estimated incidence of 4.7 per 100,000 per year and a prevalence of about 2 per 1,000 individuals. It is more common in females, accounting for roughly 70% of cases, and most frequently occurs in young adults, with a mean age of onset around 32 years. The underlying pathophysiology involves damage to the postganglionic parasympathetic fibers that innervate the iris sphincter, followed by aberrant regeneration of fibers originally destined for the ciliary body, leading to abnormal pupillary responses.


Adie tonic pupil is usually idiopathic, though it may be associated with systemic conditions such as Holmes-Adie syndrome, which includes diminished or absent deep tendon reflexes, and Ross syndrome, which combines tonic pupil, areflexia, and segmental loss of sweating. Patients often present with incidental anisocoria, blurred near vision due to accommodative dysfunction, and photophobia.


On examination, the affected pupil demonstrates poor or absent reaction to light but constricts more effectively with accommodation and redilates slowly. In unilateral cases, anisocoria is more pronounced in bright light than in darkness. Segmental contraction of the iris sphincter may be observed on slit-lamp examination. Approximately 10% of patients may show no light response at all. Deep tendon reflexes should be assessed to evaluate for associated syndromes. A comprehensive ophthalmic examination is essential, including evaluation of ocular motility and eyelid position, to exclude other serious conditions such as third nerve palsy or Horner syndrome.


Diagnosis is primarily clinical but can be supported by pharmacologic testing. Instillation of dilute pilocarpine (0.125%) causes constriction of the affected pupil due to denervation supersensitivity, while the normal pupil shows little or no response. This test is positive in the majority of patients. Laboratory investigations are generally unnecessary unless atypical features suggest an alternative underlying cause.


The differential diagnosis includes secondary tonic pupil due to inflammation, infection, ischemia, trauma, or generalized neuropathy, as well as physiologic anisocoria, third nerve palsy, pharmacologic dilation, and structural iris damage. Careful history and examination are essential to rule out these conditions, especially in bilateral or atypical cases.


Management is usually conservative, as the condition is benign. Dilute pilocarpine drops may be used to alleviate photophobia and improve near vision by constricting the pupil. Referral to neurology or neuro-ophthalmology may be warranted if the diagnosis is uncertain. Patients should be followed periodically, particularly in the early stages, to monitor for development of light-near dissociation or emergence of underlying systemic conditions. The prognosis is excellent, with most patients experiencing stable symptoms over time without significant visual impairment.

​

Ophthalmology – Acute Retinal Necrosis (Necrotizing Herpetic Retinitis)


Acute retinal necrosis is a severe, vision-threatening infectious retinitis caused by members of the herpes virus family, most commonly varicella zoster virus and herpes simplex virus. It is characterized by a combination of anterior uveitis, vitritis, and rapidly progressive peripheral retinal necrosis that spreads circumferentially and posteriorly, often accompanied by occlusive retinal vasculitis and a high risk of retinal detachment. Despite being a rare condition, with an estimated incidence of approximately 1 case per 1.6–2.0 million individuals, it typically affects otherwise healthy, immunocompetent individuals and shows a bimodal age distribution, most commonly occurring around ages 20 and 50.


Risk factors include a history of herpetic infections such as herpes simplex keratitis, herpes zoster ophthalmicus, cold sores, chickenpox, encephalitis, or shingles. Although immunodeficiency may contribute, most cases occur in immunocompetent patients. Genetic predispositions have been described, with certain HLA types associated with different populations and disease severity. The pathophysiology involves reactivation or primary infection of herpes viruses, which travel via axonal pathways to the retina, leading to viral replication within retinal cells. This results in full-thickness retinal necrosis, intranuclear viral inclusions, and both granulomatous and non-granulomatous inflammation affecting ocular tissues.


Patients may initially present with relatively mild symptoms such as eye redness, irritation, photophobia, floaters, and periorbital pain, although many experience sudden vision loss. On examination, there is often evidence of anterior uveitis, including keratic precipitates and inflammatory activity in the anterior chamber, as well as vitritis. Within days, characteristic posterior segment findings develop, including multifocal, well-demarcated patches of yellow-white retinal necrosis in the peripheral retina. These lesions rapidly progress circumferentially and posteriorly, often sparing the macula initially. Retinal vasculitis with vascular sheathing and hemorrhages may also be present. Over time, complications such as proliferative vitreoretinopathy lead to retinal breaks and rhegmatogenous retinal detachment, which occurs in more than half of cases, typically within one to two months. Bilateral involvement is seen in about 20% of patients at presentation, and without treatment, the second eye may become affected within months.


Diagnosis is primarily clinical, guided by established criteria that include peripheral retinal necrosis, rapid progression, occlusive vasculopathy, and significant intraocular inflammation. Laboratory confirmation can be achieved using polymerase chain reaction testing of aqueous or vitreous samples, which provides high sensitivity and specificity for identifying viral DNA. Other diagnostic methods, such as antibody testing or cultures, may support the diagnosis but are less definitive. Serial fundus photography is useful for monitoring disease progression, and careful examination of both eyes is essential due to the risk of bilateral spread.


The differential diagnosis includes other infectious and inflammatory retinal conditions such as progressive outer retinal necrosis, cytomegalovirus retinitis, toxoplasmosis, syphilitic retinitis, Behçet disease, sarcoidosis, intraocular lymphoma, and fungal endophthalmitis. Management requires urgent antiviral therapy to limit retinal destruction and reduce complications. Treatment traditionally involved intravenous acyclovir followed by prolonged oral therapy, but newer regimens include oral antivirals such as valacyclovir or famciclovir, often combined with intravitreal antiviral injections such as foscarnet or ganciclovir. Adjunctive corticosteroids are frequently used to control inflammation, and topical steroids are commonly administered for anterior segment involvement.


Patients should be urgently referred to a retinal or uveitis specialist due to the aggressive nature of the disease and the potential need for surgical intervention. Prophylactic laser retinopexy may be considered to reduce the risk of retinal detachment, although its benefit remains debated. Vitrectomy is indicated in cases of dense vitreous opacities, hemorrhage, or established retinal detachment. Close monitoring is essential, particularly during the early course, to detect progression, bilateral involvement, or complications.


The prognosis remains guarded despite advances in antiviral therapy, with many patients experiencing significant vision loss. Retinal detachment is the most common and serious complication, and visual outcomes are often poor, with a substantial proportion of patients developing vision worse than 20/200 over time. Other complications include optic nerve involvement, vitreous hemorrhage, retinal neovascularization, and eventual blindness. Early recognition and aggressive treatment are critical to improving outcomes and preserving vision.

​

Ophthalmology – Acute Anterior Uveitis


Acute anterior uveitis is an inflammatory condition involving the iris alone (iritis) or both the iris and ciliary body (iridocyclitis), with a sudden onset and a limited course typically lasting from days to weeks, and by definition less than three months. It is one of the most common forms of uveitis and presents with intraocular inflammation that leads to pain, redness, photophobia, and blurred vision. The condition has an incidence of approximately 17 cases per 100,000 people and a prevalence of about 38 per 100,000 in developed countries, though these figures vary depending on geographic and population factors.


A significant proportion of cases are associated with genetic predisposition, particularly the HLA-B27 phenotype, which is present in about half of affected individuals in certain populations. The underlying pathophysiology involves inflammation of the anterior uveal tract, resulting in breakdown of the blood–aqueous barrier and accumulation of inflammatory cells and proteins in the anterior chamber. The causes are diverse and include autoimmune diseases, infections, trauma, surgery, medications, and lens-related conditions, although up to half of cases remain idiopathic.


Acute anterior uveitis is frequently associated with systemic conditions, especially HLA-B27-related diseases such as ankylosing spondylitis, reactive arthritis, psoriatic arthritis, and inflammatory bowel disease. Other associations include sarcoidosis, syphilis, Lyme disease, tuberculosis, HIV infection, collagen vascular diseases, and juvenile idiopathic arthritis. A thorough history is essential and should explore systemic symptoms, prior episodes, medication use, infectious exposures, and family history of autoimmune or inflammatory disease.


Clinically, patients typically present with ocular pain, redness, photophobia, and decreased vision. On examination, ciliary flush is often seen, reflecting increased blood flow around the limbus. Pupillary constriction (miosis) may be present, and keratic precipitates can be observed on the corneal endothelium, appearing either fine or large “mutton-fat” deposits in granulomatous inflammation. The anterior chamber shows inflammatory cells and flare, and in some cases hypopyon may be present, particularly in HLA-B27-related disease or Behçet disease. Iris nodules, stromal atrophy from prior inflammation, and posterior synechiae (adhesions between the iris and lens) may also be observed. Intraocular pressure may be either elevated or reduced. A dilated fundus examination is necessary to exclude posterior segment involvement, which would suggest a broader classification such as panuveitis.


Investigations are guided by clinical suspicion. Laboratory testing is typically reserved for severe, recurrent, bilateral, or granulomatous cases and may include complete blood count, ESR, tuberculosis testing, syphilis serology, Lyme serology, HLA-B27 typing, ANA, ACE levels, and HIV testing. Imaging such as chest X-ray or CT scan may be used to evaluate for sarcoidosis or tuberculosis. The differential diagnosis is broad and includes idiopathic uveitis, HLA-B27-associated uveitis, infectious causes (viral, bacterial, fungal, or parasitic), sarcoidosis, Behçet disease, systemic lupus erythematosus, juvenile idiopathic arthritis, trauma-related inflammation, lens-induced uveitis, Fuchs heterochromic iridocyclitis, Posner-Schlossman syndrome, and masquerade syndromes such as leukemia or lymphoma.


Management focuses on controlling inflammation, relieving symptoms, and preventing complications. Corticosteroids are the mainstay of treatment, most commonly administered topically, with dosing depending on severity. In more severe or refractory cases, periocular or systemic corticosteroids may be required. Cycloplegic and mydriatic agents are used to relieve pain from ciliary spasm, prevent the formation of posterior synechiae, and stabilize the blood–aqueous barrier. In cases resistant to steroids or requiring long-term control, immunosuppressive agents or biologic therapies may be used in collaboration with specialists. Elevated intraocular pressure is treated with appropriate medications, avoiding prostaglandin analogues due to their potential pro-inflammatory effects, and topical NSAIDs may be used for associated cystoid macular edema.


Patients require close follow-up to monitor visual acuity, intraocular inflammation, and response to treatment. The frequency of visits and medications is gradually reduced as inflammation resolves. Complications can arise from both the disease and its treatment and include cataract formation, glaucoma due to trabecular damage or synechiae, hypotony from ciliary body dysfunction, and cystoid macular edema. With prompt diagnosis and appropriate management, most cases can be effectively controlled, although recurrence is common, particularly in patients with underlying systemic disease.

​

​Ophthalmology – Acne Rosacea


Acne rosacea is a chronic inflammatory acneiform disorder that primarily affects the central face, including the nose, cheeks, chin, forehead, and may also involve the eyelids and ocular surface. It commonly presents with facial flushing, persistent erythema, papules, pustules, and a sensation of burning or stinging, often accompanied by dry skin. Ocular involvement is frequent and may manifest as blepharoconjunctivitis with meibomian gland dysfunction, lid margin telangiectasia, recurrent hordeola or chalazia, conjunctival hyperemia, and irritation. In more severe cases, the cornea may be affected, leading to punctate epithelial keratitis, vascularization, infiltration, ulceration, or even perforation. Less commonly, inflammation may extend to the episclera, sclera, or iris.


Rosacea affects approximately 1 in 20 individuals, most commonly between the ages of 30 and 60 years, with no clear sex predilection. It is thought to be more prevalent in fair-skinned individuals of European or Celtic descent, although this may be underrecognized in darker skin due to masking by pigmentation. While no single causative gene has been identified, there is often a familial tendency. The exact etiology remains unclear, with proposed contributing factors including vascular dysregulation, immune and inflammatory mechanisms, environmental triggers, and possibly microorganisms such as Demodex folliculorum. Pathophysiologically, abnormal vascular responses lead to vasodilation and leakage of plasma, which promotes inflammation.


Patients often report a history of facial flushing triggered by environmental or lifestyle factors such as sun exposure, wind, extreme temperatures, exercise, stress, alcohol, or spicy foods. On examination, characteristic findings include diffuse erythema, telangiectasias, inflammatory papules and pustules, and in advanced cases, hypertrophy of sebaceous glands resulting in rhinophyma, which is thickening and purplish discoloration of the nasal skin. Ocular examination may reveal chronic eyelid inflammation, meibomian gland obstruction, and signs of conjunctival or corneal involvement.


Diagnosis is primarily clinical and does not require laboratory testing. Histopathological findings, when assessed, include vascular dilation, perivascular inflammatory infiltrates composed of lymphocytes, plasma cells, and histiocytes, and degeneration of dermal connective tissue with edema and elastosis. In rhinophyma, there is an increase in sebaceous gland tissue. Differential diagnoses include acne vulgaris, lupus erythematosus, seborrheic dermatitis, erysipelas, dermatitis, carcinoid syndrome, tuberculosis, and syphilis.


Management focuses on controlling symptoms and preventing progression, as rosacea is a chronic condition without a definitive cure. First-line treatment typically includes oral tetracyclines such as doxycycline or minocycline, which have both antimicrobial and anti-inflammatory effects. Topical therapies such as metronidazole, azelaic acid, or sodium sulfacetamide may also be used. Lid hygiene is essential in patients with ocular involvement, along with lubricants and, in some cases, short-term topical corticosteroids. More severe or refractory cases may require oral isotretinoin or procedural interventions such as electrocautery for telangiectasias.


Patients should be advised to avoid known triggers, use daily sunscreen, and adopt gentle skincare practices. Dietary modifications, including limiting spicy foods, alcohol, and hot beverages, may help reduce flare-ups. Referral to ophthalmology is important in cases with significant ocular involvement, particularly when there is corneal disease or recurrent eyelid lesions, and dermatology referral may be necessary for severe cutaneous disease or rhinophyma requiring surgical or laser treatment.


Regular follow-up is important to monitor for complications, especially corneal involvement, which can threaten vision if untreated. The overall prognosis is good with appropriate management, although symptoms tend to be chronic and relapsing. Key clinical insights include recognizing that recurrent chalazia or hordeola may indicate underlying ocular rosacea, and that long-term management often relies on a combination of topical and systemic antibiotic therapy along with lifestyle modification.

Ophthalmology – Achromatopsia


Achromatopsia is a congenital retinal disorder characterized by reduced or absent color vision due to defective cone photoreceptor function. It presents with photophobia, decreased visual acuity, nystagmus, eccentric fixation, and a small central scotoma. The condition may be classified into complete and incomplete forms, depending on the degree of residual cone function. It typically manifests in infancy, often with fine nystagmus and marked light sensitivity, and children may prefer dim lighting, sometimes being described as “night owls.” Visual acuity is usually reduced, commonly around 20/200, and color discrimination is severely impaired.


The condition has an estimated incidence of approximately 1 in 30,000 individuals and follows an autosomal recessive inheritance pattern. Risk factors include consanguinity and a positive family history. Several genetic mutations have been identified, including CNGA3, CNGB3 (notably the Pingelap variant), GNAT2, and others, all affecting proteins involved in cone phototransduction. The underlying pathophysiology involves reduced or absent expression of these proteins in cone photoreceptors, leading to disruption of the normal phototransduction cascade and abnormal cone development.


Clinically, patients exhibit high-frequency nystagmus that may lessen with age, significant photophobia, and reduced visual acuity. Hyperopia may be present, and fundus examination is often normal or shows only subtle changes such as minimal foveal hypoplasia or mild pigmentary alterations. Color vision testing reveals impairment across all axes (protan, deutan, and tritan). Full-field electroretinography typically demonstrates absent or markedly reduced photopic (cone-mediated) responses with relatively preserved scotopic (rod-mediated) responses. Visual field testing may show a small central scotoma, and optical coherence tomography may appear normal or show mild macular thinning. Additional imaging such as fluorescein angiography and fundus autofluorescence is usually normal.


Diagnosis is supported by clinical findings and can be confirmed with molecular genetic testing. Neuroimaging may be considered in atypical cases, particularly when nystagmus presentation is unusual, to exclude intracranial pathology. Histopathologically, there is a reduced number of cones, and the remaining cones are structurally abnormal.


Differential diagnoses include incomplete achromatopsia, which retains partial cone function and better visual acuity; blue-cone monochromatism, which is X-linked and can be differentiated by specialized color testing or electroretinography; cone monochromatism; cone dystrophy, which shows progressive deterioration rather than congenital onset; and cone-rod dystrophy, which includes rod involvement over time. Other considerations include foveal hypoplasia and cerebral achromatopsia, the latter typically associated with neurological events such as trauma or febrile illness.


There is no specific medical treatment for achromatopsia. Management focuses on supportive measures, including the use of dark or tinted glasses or red-tinted contact lenses to reduce photophobia, although these may not always be well tolerated. Low vision aids are beneficial, and children may require educational support such as individualized learning plans. Correction of refractive error is important, and patients should be referred for genetic counseling and low vision services as needed.


Regular follow-up is recommended, particularly in children, with ophthalmic evaluations every 6 to 12 months to monitor visual function and refractive status. The prognosis is generally stable, with visual acuity remaining relatively constant over time, although mild degeneration may occur later in life due to age-related photoreceptor loss. Nystagmus and photophobia may improve slightly with age. The main complications include persistent low vision and significant light sensitivity, which can impact daily functioning and quality of life.

​

Ophthalmology – Amblyopia


Amblyopia is a developmental visual disorder characterized by decreased best-corrected visual acuity in one or both eyes that cannot be explained by structural abnormalities of the eye alone. It arises during the critical period of visual development in early childhood, typically within the first decade of life, when abnormal visual input leads to impaired visual processing. Importantly, amblyopia is potentially reversible if detected and treated early. It is the leading cause of monocular visual loss in children and young to middle-aged adults, affecting approximately 2–4% of the population, with a lifetime risk of visual impairment of about 1.2%.


The condition develops due to abnormal visual experience, most commonly from anisometropia (unequal refractive error between the eyes), strabismus (ocular misalignment), or a combination of both. Other causes include high bilateral refractive error or visual deprivation from conditions such as congenital cataracts or ptosis during the critical period. Anisometropia is a particularly strong risk factor, especially when refractive differences exceed certain thresholds. The underlying pathophysiology involves competitive interaction between the eyes, leading to suppression of the weaker eye. This results in structural and functional changes in the visual pathway, including atrophy of neurons in the lateral geniculate nucleus and reduced responsiveness of cortical neurons in the visual cortex.


Patients may present with reduced vision in one eye, although many cases are detected through screening rather than symptoms. In preverbal children, a strong fixation preference for one eye may be noted. Diagnosis requires identification of reduced visual acuity, typically at least a two-line difference between the eyes, in the presence of a risk factor such as anisometropia or strabismus. A key clinical feature is the “crowding phenomenon,” where visual acuity is worse when multiple letters are presented together compared to single optotypes. A comprehensive eye examination, including cycloplegic refraction and assessment for strabismus, is essential to confirm the diagnosis and exclude organic causes of visual loss.


Investigations are generally not required unless there is suspicion of underlying neurological or retinal pathology. In selected cases, optical coherence tomography or electrophysiological tests such as visual evoked potentials or electroretinography may be used to rule out organic disease. The differential diagnosis includes uncorrected refractive error, organic ocular or neurological disease, and poor compliance with treatment.


Management focuses on correcting the underlying cause and promoting use of the amblyopic eye. Initial treatment includes full refractive correction with glasses or contact lenses, which alone may significantly improve vision in many patients. Additional therapy involves occlusion of the dominant eye using patching or pharmacologic penalization with atropine drops to blur the better eye. Both methods have been shown to produce similar improvements in visual acuity. The duration and intensity of treatment depend on the severity of amblyopia and the child’s age, with closer follow-up required in younger patients. Compliance is critical and may require behavioral strategies and parental support.


In cases where amblyopia is secondary to structural abnormalities, such as cataracts or ptosis, surgical correction may be necessary, followed by amblyopia therapy. Alternative methods to traditional patching include Bangerter filters, occlusive contact lenses, or spectacle-mounted occluders. Experimental treatments such as L-Dopa have been studied but are not standard of care.


Regular follow-up is essential to monitor improvement, ensure compliance, and prevent complications such as occlusion amblyopia in the treated eye. Treatment is typically tapered once maximal improvement is achieved. Prognosis is generally favorable, particularly when treatment is initiated before 7 years of age. Many patients achieve significant improvement, with a substantial proportion reaching near-normal vision. However, outcomes depend on factors such as baseline visual acuity, severity of refractive error, and adherence to therapy.


Complications of treatment are uncommon but may include temporary reduction of vision in the patched eye, skin irritation from patches, systemic side effects from atropine, and psychosocial challenges related to treatment. Early detection through routine vision screening and timely intervention remain the most important factors in achieving optimal visual outcomes.

​

Ophthalmology – Amaurosis Fugax


Amaurosis fugax refers to transient monocular vision loss caused by temporary ischemia or vascular insufficiency affecting the retina or optic nerve. It is often described as a sudden, painless loss of vision in one eye that typically lasts seconds to minutes and resolves completely. Patients frequently describe the experience as a “curtain” descending over the visual field, most commonly affecting the upper field, although other patterns such as patchy or sectoral vision loss may occur. Recurrent episodes often follow a similar pattern. This condition is clinically significant because it is often a warning sign of underlying vascular disease and an increased risk of stroke.


Approximately 50,000 new cases occur annually in the United States, and major risk factors include hypertension, hypercholesterolemia, diabetes, and smoking. The underlying pathophysiology involves transient interruption of blood flow to the retina or optic nerve. The most common mechanism is thromboembolism, typically originating from atherosclerotic plaques in the ipsilateral carotid artery or from cardiac sources such as valvular disease or intracardiac thrombi. Other mechanisms include hemodynamic compromise due to reduced perfusion, vasospasm (as in retinal migraine), or abnormalities in blood viscosity or coagulability. Ocular causes such as anterior ischemic optic neuropathy, central retinal vein occlusion, or severe hypertension may also present with similar transient visual symptoms.


A detailed history is critical to confirm the diagnosis and distinguish it from other causes of transient vision loss. Key features include sudden onset, monocular involvement, brief duration, and complete recovery. Associated symptoms suggestive of systemic conditions, particularly giant cell arteritis in patients over 55 years old, should be actively sought, including scalp tenderness, jaw claudication, fever, weight loss, and muscle weakness. Physical examination should include measurement of blood pressure, cardiac and carotid auscultation, and palpation of temporal arteries. A comprehensive ophthalmic examination is essential to evaluate for signs of retinal ischemia, such as pallor, hemorrhages, cotton wool spots, or visible emboli such as Hollenhorst plaques.


Urgent diagnostic evaluation is required to identify the underlying cause and reduce the risk of stroke. Laboratory tests include complete blood count, inflammatory markers such as ESR and CRP to rule out giant cell arteritis, lipid profile, and diabetes screening. In selected cases, evaluation for hypercoagulable states may be indicated. Imaging studies are crucial, with carotid duplex ultrasound used to assess for carotid artery stenosis or plaque. Additional imaging such as CT or MR angiography may be performed to evaluate cerebral and vascular anatomy. Cardiac evaluation with echocardiography and electrocardiography is important to identify potential embolic sources. Fluorescein angiography may be used to document retinal ischemia in uncertain cases.


Management focuses on preventing future ischemic events, particularly stroke. Antiplatelet therapy, such as aspirin, is commonly used to reduce the risk of recurrent events. Control of modifiable risk factors, including blood pressure, cholesterol, and smoking cessation, is essential. In cases of carotid artery stenosis, treatment depends on the severity: medical management for mild to moderate stenosis, and carotid endarterectomy for significant stenosis, particularly when greater than 70% or associated with symptoms. If a cardiac source is identified, appropriate management such as anticoagulation may be required. In suspected giant cell arteritis, immediate initiation of high-dose corticosteroids is critical to prevent permanent vision loss.


The prognosis depends on the underlying cause and timely intervention. Amaurosis fugax is an important predictor of future stroke, with an estimated annual stroke risk of approximately 2%. With appropriate treatment, including surgical intervention when indicated, the risk of stroke can be significantly reduced. However, procedures such as carotid endarterectomy carry their own risks, including stroke and death. Overall, prompt recognition and comprehensive systemic evaluation are essential to prevent serious neurological complications.

​

Ophthalmology – Alport Syndrome


Alport syndrome is a hereditary disorder characterized by a triad of progressive kidney disease (glomerulonephritis), sensorineural hearing loss, and ocular abnormalities. It is caused by mutations affecting type IV collagen, an essential structural component of basement membranes in the kidney, cochlea, cornea, and retina. The condition most commonly follows an X-linked recessive inheritance pattern, with mutations in the COL4A5 gene, although autosomal recessive and dominant forms involving COL4A3 and COL4A4 also occur. It affects approximately 1 in 5,000 individuals, with males more severely affected, and many patients progressing to end-stage renal failure and significant hearing loss by around 40 years of age.


The underlying pathophysiology involves structural abnormalities in basement membranes due to defective type IV collagen, leading to progressive dysfunction of affected organs. In the kidneys, this results in chronic glomerulonephritis, while in the inner ear it leads to high-frequency hearing loss that gradually worsens. In the eye, abnormalities arise from similar structural defects affecting ocular tissues.


Patients often present initially with hematuria, which may be microscopic in childhood or episodic gross hematuria associated with infections. Over time, proteinuria, nephrotic syndrome, hypertension, and eventual renal failure may develop. Hearing loss typically begins in late childhood or adolescence and progresses over time. Ocular manifestations are diverse and can provide important diagnostic clues. The most characteristic findings include anterior lenticonus, which is highly suggestive of Alport syndrome, and a dot-and-fleck retinopathy, which is usually asymptomatic. Posterior polymorphous corneal dystrophy may also be present. Other ocular findings include cataracts, corneal abnormalities, retinal pigmentation changes, microcornea, and rarely spontaneous lens rupture.


Diagnosis is based on a combination of clinical features, family history, and investigations. Urinalysis typically reveals hematuria and proteinuria, while blood tests assess renal function. Audiometry detects sensorineural hearing loss, and ophthalmologic examination identifies characteristic eye findings. Renal biopsy may show changes in the glomerular basement membrane, particularly thickening and irregularity on electron microscopy. Genetic testing can confirm the diagnosis and identify carriers within families.


The differential diagnosis depends on the presenting features and includes other causes of hereditary nephritis, retinopathies, and corneal dystrophies. For example, dot-and-fleck retinopathy must be distinguished from other retinal conditions, and anterior lenticonus must be differentiated from more common lens changes such as nuclear sclerosis.


Management is multidisciplinary and focuses on supportive care and treatment of complications. Renal disease may require dialysis or kidney transplantation in advanced stages. Hearing aids are used for auditory impairment. Ocular management includes correction of refractive errors, cataract surgery if needed, and monitoring of corneal conditions. Retinal findings typically do not require treatment as they are usually asymptomatic.


Regular follow-up with ophthalmology, nephrology, and audiology is essential, and family members should be screened for early signs such as microscopic hematuria. The prognosis varies depending on the genetic subtype, but males with X-linked disease often experience progressive renal failure and hearing loss, while females may have milder disease. Visual prognosis is generally good, although some patients may develop vision-threatening complications. Overall, morbidity is largely driven by renal and auditory involvement, with ocular findings serving as important diagnostic markers.

​